OpGen
    • Facebook
    • Linkedin
    • Twitter
    • YouTube
Illustration of doctor and patient

Cutting edge infectious disease molecular diagnostics to improve patient care.

Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR).

We provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).

Together we improve patient care and fight AMR through cutting edge molecular microbiology.

Explore

Together we improve patient care and fight AMR through cutting edge molecular microbiology.

OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes.

OpGen’s product portfolio includes the Curetis Unyvero System and multiplex syndromic panels, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb using next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Unyvero cartridge

Unyvero

Fast & simple syndromic testing for severe infections

DNA

ARESdb

AI-powered bioinformatics to help revolutionize antimicrobial stewardship

Acuitas image

Acuitas

Comprehensive resistance gene detection to aid in the management of patients

Blue bkdg

OpGen in the News


Learn More

green bkgd

Product Videos


Watch

Blue bkgd

Publications


Read More

Press Releases

  • 9.15.21
    OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia  MORE
  • 8.12.21
    OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update  MORE
  • 8.4.21
    OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting  MORE

See all news

Earnings Events

    There are currently no upcoming events.

    See all events

    Corporate Videos

    • OpGen – Edison Open House: Global Healthcare 2021 – YouTube
    • OpGen CEO Oliver Schacht Appears on Infection Control Today – YouTube
    • OpGen CEO Oliver Schacht Appears on EdisonTV to Discuss the Future of the Combined Company – YouTube

    Watch

    Contact Us

    For more information on our products and services:
    • This field is for validation purposes and should be left unchanged.